Trial Profile
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2016 New trial record